Skip to main content
Clinical Trials/NCT05835921
NCT05835921
Recruiting
Not Applicable

Enhancing Prospective Thinking in Early Recovery

Indiana University1 site in 1 country88 target enrollmentMarch 28, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Stimulant Use
Sponsor
Indiana University
Enrollment
88
Locations
1
Primary Endpoint
Reduced Use of Drug Using Days
Status
Recruiting
Last Updated
7 months ago

Overview

Brief Summary

The goal of this clinical trial is to use a novel virtual reality intervention to test for efficacy in reducing stimulant use and increasing abstinence, with concomitant increases in future self-identification, future time perspective, and delay-of-reward, in early recovering stimulant use disorder (StUD) persons. The main question[s] this trial aims to answer are:

  • Will the Virtual Reality (VR) intervention decrease the number of stimulant use days?
  • Will the VR intervention produce longer abstinence periods during follow-up visits?
  • Will the VR intervention increase stimulant drug abstinence rates?
  • Will the VR intervention increase future self-identification?
  • Will the VR intervention increase self-reported future time perspective?
  • Will the VR intervention increase preference for delayed rewards in a laboratory delay discounting task on the study day?
  • Will the VR intervention produce gains in the behavioral effects of future self-identification, future time perspective, and delayed rewards at the 30-day and 6-month follow-ups?

Researchers will compare the experimental and control groups to see if there are differences in the results for the questions outlined above.

Registry
clinicaltrials.gov
Start Date
March 28, 2023
End Date
May 1, 2026
Last Updated
7 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Brandon G. Oberlin, PhD

Assistant Professor

Indiana University

Eligibility Criteria

Inclusion Criteria

  • Abstinence between ≥14 days and ≤1 year
  • At least 18 years old
  • Verbal endorsement of commitment to recovery
  • Outpatient
  • Psychotropic drugs for SUD-comorbidity
  • Drug/alcohol abstinence ≥ 24 hours at the time of the study day visit
  • English comprehension

Exclusion Criteria

  • Unstable medical disorders
  • Less than 18 years old
  • Habitual drug use
  • Smell/taste disorders
  • Unstable psychiatric conditions
  • Extravagant/elaborate face tattoos

Outcomes

Primary Outcomes

Reduced Use of Drug Using Days

Time Frame: Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit.

The Virtual Reality Avatar experience will reduce drug using days.

Increased Length of Abstinence

Time Frame: Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit.

The Virtual Reality Avatar experience will increase the length of abstinence periods.

Increased (overall) Abstinence

Time Frame: Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit.

The Virtual Reality Avatar experience will increase abstinence.

Future Self-identification

Time Frame: Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit.

The Virtual Reality Avatar experience will increase future self-identification.

Delayed Reward Preference

Time Frame: Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit.

The Virtual Reality Avatar experience will increase preference for delayed rewards.

Future Time Perspective

Time Frame: Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit.

The Virtual Reality Avatar experience will increase future time perspective.

Study Sites (1)

Loading locations...

Similar Trials